Antag Secures $84M to Advance Obesity Treatment AT-7687 with Novo Holdings' Backing

Antag Therapeutics, a Danish startup focused on obesity treatment, has successfully raised €80 million (approximately $84 million) in its Series A funding round, which was notably led by Versant Ventures with additional participation from Novo Holdings and other investors. This substantial financial support will propel the advancement of Antag's flagship program, AT-7687, into phase 1 clinical trials. The strategic backing from notable investors such as Novo Holdings is critical, providing a strong foundation and validation for Antag as it ventures into an obesity market largely dominated by GLP-1-based treatments from companies like Eli Lilly and Novo Nordisk. The funding underscores an important milestone for Antag, amplifying its capacity to explore more effective and tolerable drug combinations for obesity treatment beyond current market offerings[1][2][3].